EA202092830A1 - Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения - Google Patents
Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного примененияInfo
- Publication number
- EA202092830A1 EA202092830A1 EA202092830A EA202092830A EA202092830A1 EA 202092830 A1 EA202092830 A1 EA 202092830A1 EA 202092830 A EA202092830 A EA 202092830A EA 202092830 A EA202092830 A EA 202092830A EA 202092830 A1 EA202092830 A1 EA 202092830A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bcma
- specific antibodies
- combined use
- antiproliferative compounds
- human
- Prior art date
Links
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title abstract 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- YTINZZFBHWSAGL-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O YTINZZFBHWSAGL-UHFFFAOYSA-N 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 102000046935 human TNFRSF17 Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675639P | 2018-05-23 | 2018-05-23 | |
| PCT/US2019/033505 WO2019226761A1 (en) | 2018-05-23 | 2019-05-22 | Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092830A1 true EA202092830A1 (ru) | 2021-04-08 |
Family
ID=66999900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092830A EA202092830A1 (ru) | 2018-05-23 | 2019-05-22 | Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11439637B2 (ja) |
| EP (2) | EP3796912B1 (ja) |
| JP (2) | JP7293256B2 (ja) |
| KR (1) | KR20210021996A (ja) |
| CN (2) | CN112399848A (ja) |
| AU (1) | AU2019274530A1 (ja) |
| BR (1) | BR112020023704A2 (ja) |
| CA (1) | CA3101050A1 (ja) |
| CY (1) | CY1126060T1 (ja) |
| DK (1) | DK3796912T3 (ja) |
| EA (1) | EA202092830A1 (ja) |
| ES (1) | ES2945214T3 (ja) |
| FI (1) | FI3796912T3 (ja) |
| HR (1) | HRP20230449T1 (ja) |
| HU (1) | HUE061792T2 (ja) |
| IL (1) | IL278853A (ja) |
| LT (1) | LT3796912T (ja) |
| MX (1) | MX2020012485A (ja) |
| PL (1) | PL3796912T3 (ja) |
| PT (1) | PT3796912T (ja) |
| RS (1) | RS64189B1 (ja) |
| SG (1) | SG11202011545YA (ja) |
| SI (1) | SI3796912T1 (ja) |
| WO (1) | WO2019226761A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202011568XA (en) | 2018-05-23 | 2020-12-30 | Celgene Corp | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile |
| EP3908582A1 (en) * | 2019-01-09 | 2021-11-17 | Celgene Corporation | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| EA202191904A1 (ru) * | 2019-01-09 | 2021-10-04 | Селджин Корпорейшн | Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения |
| AU2021209727B2 (en) * | 2020-01-20 | 2024-01-11 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| KR20230015921A (ko) * | 2020-04-28 | 2023-01-31 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂｃｍａ-지시된 ｔ 세포 요법 및 면역 조절 화합물의 조합 |
| IL297716A (en) | 2020-04-30 | 2022-12-01 | Bristol Myers Squibb Co | Preparations for the treatment of side effects related to cytokines |
| JP2021186294A (ja) * | 2020-05-29 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
| US20220233690A1 (en) | 2021-01-28 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| KR102405104B1 (ko) | 2015-04-13 | 2022-06-07 | 화이자 인코포레이티드 | 치료 항체 및 그의 용도 |
| WO2017021450A1 (en) * | 2015-08-03 | 2017-02-09 | Engmab Ag | Monoclonal antibodies against bcma |
| US10238225B2 (en) * | 2016-06-08 | 2019-03-26 | Windor Enterprises, LLC | Compression garment donning aid device, method, and kit |
| WO2018075820A2 (en) | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| BR112019008426A2 (pt) * | 2016-11-02 | 2019-09-03 | Engmab Sarl | anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo |
| BR112020000442A2 (pt) * | 2017-07-10 | 2020-07-21 | Celgene Corporation | compostos antiproliferativos e métodos de uso dos mesmos |
-
2019
- 2019-05-22 SI SI201930535T patent/SI3796912T1/sl unknown
- 2019-05-22 DK DK19732494.0T patent/DK3796912T3/da active
- 2019-05-22 US US16/419,971 patent/US11439637B2/en active Active
- 2019-05-22 BR BR112020023704-3A patent/BR112020023704A2/pt unknown
- 2019-05-22 JP JP2020565359A patent/JP7293256B2/ja active Active
- 2019-05-22 EA EA202092830A patent/EA202092830A1/ru unknown
- 2019-05-22 FI FIEP19732494.0T patent/FI3796912T3/fi active
- 2019-05-22 AU AU2019274530A patent/AU2019274530A1/en active Pending
- 2019-05-22 CN CN201980046500.XA patent/CN112399848A/zh active Pending
- 2019-05-22 EP EP19732494.0A patent/EP3796912B1/en active Active
- 2019-05-22 PT PT197324940T patent/PT3796912T/pt unknown
- 2019-05-22 RS RS20230351A patent/RS64189B1/sr unknown
- 2019-05-22 HU HUE19732494A patent/HUE061792T2/hu unknown
- 2019-05-22 HR HRP20230449TT patent/HRP20230449T1/hr unknown
- 2019-05-22 ES ES19732494T patent/ES2945214T3/es active Active
- 2019-05-22 EP EP23156579.7A patent/EP4218762A3/en active Pending
- 2019-05-22 WO PCT/US2019/033505 patent/WO2019226761A1/en unknown
- 2019-05-22 PL PL19732494.0T patent/PL3796912T3/pl unknown
- 2019-05-22 CA CA3101050A patent/CA3101050A1/en active Pending
- 2019-05-22 CN CN202110586843.4A patent/CN113713095A/zh active Pending
- 2019-05-22 KR KR1020207036733A patent/KR20210021996A/ko unknown
- 2019-05-22 LT LTEPPCT/US2019/033505T patent/LT3796912T/lt unknown
- 2019-05-22 MX MX2020012485A patent/MX2020012485A/es unknown
- 2019-05-22 SG SG11202011545YA patent/SG11202011545YA/en unknown
-
2020
- 2020-11-20 IL IL278853A patent/IL278853A/en unknown
-
2022
- 2022-08-17 US US17/820,534 patent/US20230181575A1/en active Pending
-
2023
- 2023-05-15 CY CY20231100227T patent/CY1126060T1/el unknown
- 2023-06-07 JP JP2023093659A patent/JP2023116613A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11439637B2 (en) | 2022-09-13 |
| BR112020023704A2 (pt) | 2021-02-17 |
| DK3796912T3 (da) | 2023-05-15 |
| LT3796912T (lt) | 2023-06-12 |
| EP4218762A3 (en) | 2023-08-16 |
| RS64189B1 (sr) | 2023-06-30 |
| CN113713095A (zh) | 2021-11-30 |
| WO2019226761A1 (en) | 2019-11-28 |
| JP2023116613A (ja) | 2023-08-22 |
| CN112399848A (zh) | 2021-02-23 |
| EP4218762A2 (en) | 2023-08-02 |
| HRP20230449T1 (hr) | 2023-07-21 |
| SI3796912T1 (sl) | 2023-07-31 |
| AU2019274530A1 (en) | 2020-12-10 |
| ES2945214T3 (es) | 2023-06-29 |
| FI3796912T3 (fi) | 2023-05-11 |
| JP7293256B2 (ja) | 2023-06-19 |
| JP2021525248A (ja) | 2021-09-24 |
| PT3796912T (pt) | 2023-05-17 |
| MX2020012485A (es) | 2021-04-28 |
| HUE061792T2 (hu) | 2023-08-28 |
| EP3796912A1 (en) | 2021-03-31 |
| IL278853A (en) | 2021-01-31 |
| CA3101050A1 (en) | 2019-11-28 |
| SG11202011545YA (en) | 2020-12-30 |
| US20190381035A1 (en) | 2019-12-19 |
| EP3796912B1 (en) | 2023-02-15 |
| US20230181575A1 (en) | 2023-06-15 |
| KR20210021996A (ko) | 2021-03-02 |
| CY1126060T1 (el) | 2023-11-15 |
| PL3796912T3 (pl) | 2023-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092830A1 (ru) | Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения | |
| CO2020000193A2 (es) | Compuestos antiproliferativos y métodos para utilizarlos | |
| CR20220258A (es) | Inhibidores de kras g12c | |
| MA29595B1 (fr) | Anticorps anti-cd40 humanises et procedes d'utilisation | |
| CY1120611T1 (el) | Κρυσταλλικες μορφες 1-(5'-(5-(3,5-διχλωρο-4-φθοροφαινυλο)-5-(τριφθορομεθυλο)-4,5-διυδροϊσοξαζολ-3-υλο)-3ή-σπειρο[αζετιδιν-3,1'-ισοβενζοφουραν]-1-υλο)-2-(μεθυλοσουλφονυλ)αιθανονης | |
| MA44594B1 (fr) | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci | |
| EA201990787A1 (ru) | Биспецифичное антитело к всма и cd3 и иммунологическое лекарственное средство для комбинированного применения в лечении множественной миеломы | |
| PE20211375A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| CY1120454T1 (el) | Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος | |
| IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
| EA202091893A1 (ru) | Новые кристаллические формы | |
| EP4212532A3 (en) | Mitragynine analogs and uses thereof | |
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
| EA201892284A1 (ru) | Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств | |
| EA202191359A1 (ru) | Антагонистические моноклональные антитела к cd40 и их применения | |
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| PE20170669A1 (es) | Compuesto heterociclico | |
| MX2018007143A (es) | Formas de sales y polimorfos de (r)-1-(4-(6-(2-(4-(3,3-difluorocic lobutoxi)-6-metilpiridin-2-il)acetamido)piridazin-3-il)-2-fluorob util)-n-metil-1h-1,2,3-triazol-4-carboxamida. | |
| EA202191833A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| MX2020004025A (es) | Inhibidor del receptor del factor de crecimiento epidermico. | |
| EA202191620A1 (ru) | Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения | |
| EA201992744A1 (ru) | Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей | |
| BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
| PH12018501246A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds |